NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial

Background: Surgery remains the standard of care for localised renal cell carcinoma (RCC). Nevertheless, nearly 50% of patients with high-risk disease experience relapse after surgery, with distant sites being common. Considering improved outcomes in terms of disease-free survival with adjuvant immu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel, Arun A. Azad, Catherine Mitchell, Declan Murphy, Homi Zargar, Nick Hardcastle, Jamie Kearsley, Renu Eapen, Lih Ming Wong, Katharine Cuff, Nathan Lawrentschuk, Paul J. Neeson, Shankar Siva
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-06-01
Col·lecció:	Contemporary Clinical Trials Communications
Matèries:	Neoadjuvant Pembrolizumab Stereotactic radiotherapy Renal cell carcinoma Nephrectomy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2451865423000911
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!